Pharmacist-led medication review and falls in preterm neonates: A retrospective cohort study
Published
October 16, 2024
Paper ID
PAP-000238
Status
Published
DOI
10.65712/tmj.test000496
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on pharmacist-led medication review. Methods: We conducted a retrospective cohort study across 12 centres between 2017 and 2023. Results: 2401 participants were included (median age 64 years). Serious adverse events were rare and similar between groups. Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
Practice around pharmacist-led medication review varies widely between centres. The cost of falls to health systems is substantial. Earlier studies of pharmacist-led medication review were small or single-centre.
falls remains a leading cause of avoidable harm among preterm neonates. Earlier studies of pharmacist-led medication review were small or single-centre. Practice around pharmacist-led medication review varies widely between centres.
Discussion
Future work should test pharmacist-led medication review in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
Residual confounding cannot be excluded. Future work should test pharmacist-led medication review in a pragmatic multicentre trial.
Conclusions
Pharmacist-led medication review merits wider use for preterm neonates to improve falls.
References
1. Ahmed Y, Haddad J, et al. Tranexamic acid and medication adherence. N Engl J Med. 2024;323(4):478-1603.
2. Kaur E, Tanaka V, et al. SGLT2 inhibitors and length of stay. JAMA. 2014;100(5):566-1029.
3. Haddad V, Costa L, et al. An antibiotic stewardship programme and falls. BMJ. 2016;89(2):115-1004.
4. Lindqvist Q, Mensah Z, et al. Vitamin D supplementation and time to diagnosis. JAMA. 2012;209(7):378-1388.
5. Dubois K, Mueller X, et al. Nurse-led discharge planning and ventilator-free days. BMC Med. 2022;294(1):483-1117.
6. Haddad C, Yilmaz G, et al. An antibiotic stewardship programme and 30-day readmission. JAMA. 2016;202(4):683-1543.
7. Ibrahim I, Zhang O, et al. SGLT2 inhibitors and 30-day readmission. JAMA. 2021;344(1):892-1089.
8. Mueller D, Mueller P, et al. Delayed cord clamping and glycaemic control. Ann Intern Med. 2009;150(8):290-920.
9. Ahmed C, Tanaka U, et al. An enhanced recovery pathway and surgical site infection. N Engl J Med. 2022;157(10):415-1141.
Appendices
Ethics approval: IRB-1714.
Materials and Methods
We conducted a retrospective cohort study across 3 centres between 2020 and 2023. We conducted a retrospective cohort study across 8 centres between 2016 and 2023.
Missing data were handled with multiple imputation. We conducted a retrospective cohort study across 8 centres between 2015 and 2024.
We conducted a retrospective cohort study across 11 centres between 2014 and 2021. We conducted a retrospective cohort study across 10 centres between 2018 and 2025. The primary outcome was falls, assessed blind to allocation.
Results
falls occurred in 11% of the intervention group versus 29% of controls. 4203 participants were included (median age 74 years). Effects were consistent across prespecified subgroups.
The adjusted odds ratio was 0.50 (95% CI 0.28 to 0.70). Serious adverse events were rare and similar between groups. 1305 participants were included (median age 38 years).
falls occurred in 10% of the intervention group versus 21% of controls. Serious adverse events were rare and similar between groups. 4738 participants were included (median age 72 years). 2965 participants were included (median age 55 years).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Male | 252 | 31 | 37.1 | 0.66 |
| Centre A | 723 | 82 | 1.5 | 0.79 |
| Centre B | 134 | 119 | 1.1 | 0.97 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.81 (95% CI 0.23 to 0.81). falls occurred in 19% of the intervention group versus 19% of controls.
Serious adverse events were rare and similar between groups.